Perceptions and Representations of Vaccination Against COVID-19 (PERCECOVAC)

December 1, 2022 updated by: Centre Hospitalier Intercommunal Creteil

SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:

According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.

To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.

Study Overview

Status

Completed

Conditions

COVID-19 Acute Respiratory Distress Syndrome

Intervention / Treatment

Behavioral: Interview

Study Type

Observational

Enrollment (Actual)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Villeneuve-Saint-Georges, France
    - CHI Villeneuve-Saint-Georges

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with or without comorbidities consulting the Villeneuve Saint Georges Hospital for COVID-19 vaccination or for a scheduled consultation

Description

Inclusion Criteria:

Over 18 years of age
Patient with a scheduled appointment in consultation or at the vaccination centre
Not opposed to participation in the protocol

Exclusion Criteria:

Patient under guardianship or curatorship
Patient unable to give free and informed consent
Patient under court protection
Patient without the cognitive capacity to ensure an interview

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Perceptions, representations and experiences of Covid-19 vaccination Time Frame: 1 hour	Interview based on 6 opened questions	1 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Key elements to improve the medical discourse on vaccination Time Frame: 1 hour	Interview based on 6 opened questions	1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Intercommunal Creteil

Collaborators

Centre Hospitalier Intercommunal Villeneuve Saint Georges

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 1, 2021

Primary Completion (ACTUAL)

September 1, 2022

Study Completion (ACTUAL)

September 1, 2022

Study Registration Dates

First Submitted

May 20, 2021

First Submitted That Met QC Criteria